In the US and the EU4, patients who were not tested versus tested for BRCA1/2mut were more likely to have hormone receptor–positive (HR+)/HER2− ABC than triple-negative breast cancer, less likely to have a known family history of BRCA1/2-related cancer and were older. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.